Breast cancer is the most common cancer among women worldwide. Estrogen, a sex hormone in women plays a key role in the proliferation of cancer cells especially in post-menopausal women. Selective estrogen receptor modulators (SERMs) like tamoxifen and raloxifene are the most efficient drugs for treatment of breast cancer. These drugs bind to estrogen receptors (ER? or ER? subtypes) in as much as the same manner as estrogen does. However, these drugs are often accompanied by severe side effects. The proposed investigation aims at developing and evaluating new estrogen antagonists.
Many patients who initially respond well to highly efficacious chemotherapy eventually develop resistance and relapse despite continued treatment. These cancers acquire drug resistance to current therapies through various mechanisms such as the acquisition of mutations for example. Furthermore, some promising targets that play a crucial role in the progression of cancer have been deemed undruggable using current methods.
Antibiotic resistance represents a major health problem for society. With the expanded use of antibiotics, microorganisms have developed various mechanisms of resistance to overcome the effects of once highly effective agents. There is therefore an urgent need to identify new therapies to counteract resistant strains. The intern will design and identify new drugs that are capable of treating patients infected with bacterial strains showing resistance to current drugs used in the clinic.
Join a thriving innovation ecosystem. Subscribe now